Keating Financial Advisory Services’s Denali Therapeutics DNLI Stock Holding History
Bought
Maintained
Sold
Other funds holding DNLI
Keating Financial Advisory Services's DNLI Position: Q2 2026 in Review
Keating Financial Advisory Services reduced its Denali Therapeutics (DNLI) stake by 18% in Q2 2026, selling an estimated $123 and leaving 27 shares worth $694. The position accounts for ﹤0.01% of the portfolio, ranked #2278.
Keating Financial Advisory Services first reported a position in DNLI in Q4 2025 and has held it in 3 quarters since. 294 funds tracked by Wall St. Rank hold DNLI as of Q2 2026.
- Keating Financial Advisory Services held 27 shares of Denali Therapeutics worth $694 as of Q2 2026.
- Keating Financial Advisory Services sold 6 Denali Therapeutics shares in Q2 2026, an estimated $123.
- Denali Therapeutics made up ﹤0.01% of Keating Financial Advisory Services's portfolio in Q2 2026, its #2278 holding.
- Keating Financial Advisory Services first reported a position in Denali Therapeutics in Q4 2025 and has held it in 3 quarters since.
- 294 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2026.
Based on Keating Financial Advisory Services's 13F filing for Q2 2026, filed 11 Aug 2026.